Medical management of neurocysticercosis

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 18, 2011, Pages 2845-2856

  Takayanagui, Osvaldo Massaiti ^a   Odashima, Newton Satoru ^a   Bonato, Pierina S ^a   Lima, Jose Eduardo ^a   Lanchote, Vera Lucia ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Albendazole; Chirality; Cysticercosis; Enantiomer; Epilepsy; MRI; Pharmacokinetics; Praziquantel; Taeniasis

Indexed keywords

ALBENDAZOLE; PRAZIQUANTEL;

ALOPECIA; BRAIN INFARCTION; DEATH; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; EPILEPSY; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INTRACRANIAL HYPERTENSION; LIVER DYSFUNCTION; NEUROCYSTICERCOSIS; PLEOCYTOSIS; RASH; REVIEW; SEIZURE; SIDE EFFECT; VOMITING;

ALBENDAZOLE; ANIMALS; ANTHELMINTICS; BRAIN DISEASES; HUMANS; LIFE CYCLE STAGES; MAGNETIC RESONANCE IMAGING; NEUROCYSTICERCOSIS; PRAZIQUANTEL; SEIZURES; TAENIA SOLIUM;

EID: 81855183765     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.634801     Document Type: Review

References (100)

1. Bern C, Garcia HH, Evans C, et al. Magnitude of the disease burden from neurocysticercosis in a developing country. Clin Infect Dis 1999;29:1203-9
2. Prevention CDC. Recommendations of the International Task Force for Disease Eradication. MMWR Recomm Rep 1993;42:1-38
3. Schantz PM, Tsang VC. The US Centers for Disease Control and Prevention (CDC) and research and control of cysticercosis. Acta Trop 2003;87:161-3
4. DeGiorgio CM, Sorvillo F, Escueta SP. Neurocysticercosis in the United States: review of an important emerging infection. Neurology 2005;64:1486
5. Sorvillo F, Wilkins P, Shafir S, et al. Public health implications of cysticercosis acquired in the United States. Emerg Infect Dis 2011;17:1-6
6. Sorvillo FJ, DeGiorgio C, Waterman SH. Deaths from cysticercosis, United States. Emerg Infect Dis 2007;13:230-5
7. Escobar A. The pathology of neurocysticercosis. In: Palacios E, Rodriguez-Carbajal J, Taveras JM, editors. Cysticercosis of the Central Nervous System. Charles C. Thomas; Il: 1983. p. 27-54
8. Del Brutto OH, Sotelo J, Roman GC. Neurocysticercosis. Swets & Zeitlinger; Lisse: 1998
9. Sinha S, Sharma BS. Neurocysticercosis: a review of current status and management. J Clin Neurosci 2009;16:867-76
10. Pittella JE. Neurocysticercosis. Brain Pathol 1997;7:681-93
11. Garcia HH, Del Brutto OH. Neurocysticercosis: updated concepts about an old disease. Lancet Neurol 2005;4:653-61
12. Fleury A, Escobar A, Fragoso G, et al. Clinical heterogeneity of human neurocysticercosis results from complex interactions among parasite, host and environmental factors. Trans R Soc Trop Med Hyg 2010;104:243-50
13. Fleury A, Dessein A, Preux PM, et al. Symptomatic human neurocysticercosis-age, sex and exposure factors relating with disease heterogeneity. J Neurol 2004;251:830-7
14. Rangel R, Torres B, Del Bruto O, et al. Cysticercotic encephalitis: a severe form in young females. Am J Trop Med Hyg 1987;36:387-92
15. Garcia HH, Gonzalez AE, Evans CA, et al. Taenia solium cysticercosis. Lancet 2003;362:547-56
16. Pal DK, Carpio A, Sander JW. Neurocysticercosis and epilepsy in developing countries. J Neurol Neurosurg Psychiatry 2000;68:137-43
17. Nash TE, Del Brutto OH, Butman JA, et al. Calcific neurocysticercosis and epileptogenesis. Neurology 2004;62:1934-8
18. Carpio A, Hauser WA. Prognosis for seizure recurrence in patients with newly diagnosed neurocysticercosis. Neurology 2002;59:1730-4
19. Fleury A, Carrillo-Mezo R, Flisser A, et al. Subarachnoid basal neurocysticercosis: a focus on the most severe form of the disease. Expert Rev Anti Infect Ther 2011;9:123-33
20. Sotelo J, Marin C. Hydrocephalus secondary to cysticercotic arachnoiditis. A long-term follow-up review of 92 cases. J Neurosurg 1987;66:686-9
21. Estanol B, Corona T, Abad P. A prognostic classification of cerebral cysticercosis: therapeutic implications. J Neurol Neurosurg Psychiatry 1986;49:1131-4
22. Forlenza OV, Filho AH, Nobrega JP, et al. Psychiatric manifestations of neurocysticercosis: a study of 38 patients from a neurology clinic in Brazil. J Neurol Neurosurg Psychiatry 1997;62:612-16
23. Ciampi de Andrade D, Rodrigues CL, Abraham R, et al. Cognitive impairment and dementia in neurocysticercosis: a cross-sectional controlled study. Neurology 2010;74:1288-95
24. Takayanagui OM, Odashima NS. Clinical aspects of neurocysticercosis. Parasitol Int 2006;55(Suppl):S111-15
25. Proano-Narvaez JV, Meza-Lucas A, Mata-Ruiz O, et al. Laboratory diagnosis of human neurocysticercosis: double-blind comparison of enzyme-linked immunosorbent assay and electroimmunotransfer blot assay. J Clin Microbiol 2002;40:2115-18
26. Gekeler F, Eichenlaub S, Mendoza EG, et al. Sensitivity and specificity of ELISA and immunoblot for diagnosing neurocysticercosis. Eur J Clin Microbiol Infect Dis 2002;21:227-9
27. Garcia HH, Harrison LJ, Parkhouse RM, et al. A specific antigen-detection ELISA for the diagnosis of human neurocysticercosis. The Cysticercosis Working Group in Peru. Trans R Soc Trop Med Hyg 1998;92:411-14
28. Garcia HH, Parkhouse RM, Gilman RH, et al. Serum antigen detection in the diagnosis, treatment, and follow-up of neurocysticercosis patients. Trans R Soc Trop Med Hyg 2000;94:673-6
29. Garcia HH, Gonzalez AE, Gilman RH, et al. Circulating parasite antigen in patients with hydrocephalus secondary to neurocysticercosis. Am J Trop Med Hyg 2002;66:427-30
30. Fleury A, Hernandez M, Avila M, et al. Detection of HP10 antigen in serum for diagnosis and follow-up of subarachnoidal and intraventricular human neurocysticercosis. J Neurol Neurosurg Psychiatry 2007;78:970-4
31. Rodriguez S, Dorny P, Tsang VC, et al. Detection of Taenia solium antigens and anti-T. solium antibodies in paired serum and cerebrospinal fluid samples from patients with intraparenchymal or extraparenchymal neurocysticercosis. J Infect Dis 2009;199:1345-52
32. White AC Jr. New developments in the management of neurocysticercosis. J Infect Dis 2009;199:1261-2
33. Almeida CR, Ojopi EP, Nunes CM, et al. Taenia solium DNA is present in the cerebrospinal fluid of neurocysticercosis patients and can be used for diagnosis. Eur Arch Psychiatry Clin Neurosci 2006;256:307-10
34. Mayta H, Gilman RH, Prendergast E, et al. Nested PCR for specific diagnosis of Taenia solium taeniasis. J Clin Microbiol 2008;46:286-9
35. Del Brutto OH, Rajshekhar V, White AC Jr, et al. Proposed diagnostic criteria for neurocysticercosis. Neurology 2001;57:177-83
36. Colli BO, Carlotti CG Jr, Assirati JA Jr, et al. Surgical treatment of cerebral cysticercosis: long-term results and prognostic factors. Neurosurg Focus 2002;12:e3
37. Rangel-Castilla L, Serpa JA, Gopinath SP, et al. Contemporary neurosurgical approaches to neurocysticercosis. Am J Trop Med Hyg 2009;80:373-8
38. Husain M, Jha DK, Rastogi M, et al. Neuro-endoscopic management of intraventricular neurocysticercosis (NCC).Acta Neurochir (Wien) 2007;149:341-6
39. Goel RK, Ahmad FU, Vellimana AK, et al. Endoscopic management of intraventricular neurocysticercosis. J Clin Neurosci 2008;15:1096-101
40. Proano JV, Torres-Corzo J, Rodriguez-Della Vecchia R, et al. Intraventricular and subarachnoid basal cisterns neurocysticercosis: a comparative study between traditional treatment versus neuroendoscopic surgery. Childs Nerv Syst 2009;25:1467-75
41. Torres-Corzo JG, Tapia-Perez JH, Vecchia RR, et al. Endoscopic management of hydrocephalus due to neurocysticercosis. Clin Neurol Neurosurg 2010;112:11-16
42. Rajshekhar V. Surgical management of neurocysticercosis. Int J Surg 2010;8:100-4
43. Leite JP, Terra-Bustamante VC, Fernandes RM, et al. Calcified neurocysticercotic lesions and postsurgery seizure control in temporal lobe epilepsy. Neurology 2000;55:1485-91
44. Wichert-Ana L, Velasco TR, Terra-Bustamante VC, et al. Surgical treatment for mesial temporal lobe epilepsy in the presence of massive calcified neurocysticercosis. Arch Neurol 2004;61:1117-19
45. Velasco TR, Zanello PA, Dalmagro CL, et al. Calcified cysticercotic lesions and intractable epilepsy: a cross sectional study of 512 patients. J Neurol Neurosurg Psychiatry 2006;77:485-8
46. Bianchin MM, Velasco TR, Takayanagui OM, et al. Neurocysticercosis, mesial temporal lobe epilepsy, and hippocampal sclerosis: an association largely ignored. Lancet Neurol 2006;5:20-1
47. Nash TE, Singh G, White AC, et al. Treatment of neurocysticercosis: current status and future research needs. Neurology 2006;67:1120-7
48. Carpio A, Escobar A, Hauser WA. Cysticercosis and epilepsy: a critical review. Epilepsia 1998;39:1025-40
49. Garcia HH, Evans CA, Nash TE, et al. Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev 2002;15:747-56
50. Sotelo J, Jung H. Pharmacokinetic optimisation of the treatment of neurocysticercosis. Clin Pharmacokinet 1998;34:503-15
51. Agapejev S, Da Silva MD, Ueda AK. Severe forms of neurocysticercosis: treatment with albendazole. Arq Neuropsiquiatr 1996;54:82-93
52. Mitre E, Talaat KR, Sperling MR, et al. Methotrexate as a corticosteroid-sparing agent in complicated neurocysticercosis. Clin Infect Dis 2007;44:549-53
53. Takayanagui OM. Therapy for neurocysticercosis. Expert Rev Neurother 2004;4:129-39
54. Garcia-Dominguez C, Correa D, Rabiela MT, et al. Praziquantel treatment of muscle Taenia solium cysticercosis. 4. Reversible in vitro effect. Parasitol Res 1991;77:691-6
55. Li XQ, Bjorkman A, Andersson TB, et al. Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol 2003;59:429-42
56. Pretell EJ, Garcia HH, Custodio N, et al. Short regimen of praziquantel in the treatment of single brain enhancing lesions. Clin Neurol Neurosurg 2000;102:215-18
57. Medina-Santillan R, Mateos-Garcia E, Reyes-Garcia G, et al. Pharmacoeconomic analysis of the short scheme praziquantel in the treatment of neurocysticercosis. Gac Med Mex 2002;138:203-7
58. Del Brutto OH, Campos X, Sanchez J, et al. Single-day praziquantel versus 1-week albendazole for neurocysticercosis. Neurology 1999;52:1079-81
59. Lopez-Gomez M, Castro N, Jung H, et al. Optimization of the single-day praziquantel therapy for neurocysticercosis. Neurology 2001;57:1929-30
60. Pretell EJ, Garcia HH, Gilman RH, et al. Failure of one-day praziquantel treatment in patients with multiple neurocysticercosis lesions. Clin Neurol Neurosurg 2001;103:175-7
61. Lacey E. Mode of action of benzimidazoles. Parasitol Today 1990;6:112-15
62. Garcia HH, Gilman RH, Horton J, et al. Albendazole therapy for neurocysticercosis: a prospective double-blind trial comparing 7 versus 14 days of treatment. Cysticercosis Working Group in Peru. Neurology 1997;48:1421-7
63. Singhi P, Dayal D, Khandelwal N. One week versus four weeks of albendazole therapy for neurocysticercosis in children: a randomized, placebo-controlled double blind trial. Pediatr Infect Dis J 2003;22:268-72
64. Takayanagui OM, Jardim E. Therapy for neurocysticercosis. Comparison between albendazole and praziquantel. Arch Neurol 1992;49:290-4
65. Bang OY, Heo JH, Choi SA, et al. Large cerebral infarction during praziquantel therapy in neurocysticercosis. Stroke 1997;28:211-13
66. Takayanagui OM, Lanchote VL, Marques MP, et al. Therapy for neurocysticercosis: pharmacokinetic interaction of albendazole sulfoxide with dexamethasone. Ther Drug Monit 1997;19:51-5
67. Del Brutto OH, Roos KL, Coffey CS, et al. Meta-analysis: cysticidal drugs for neurocysticercosis: albendazole and praziquantel. Ann Intern Med 2006;145:43-51
68. Matthaiou DK, Panos G, Adamidi ES, et al. Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials. PLoS Negl Trop Dis 2008;2:e194
69. Proano JV, Madrazo I, Avelar F, et al. Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts. N Engl J Med 2001;345:879-85
70. Marquez-Caraveo C, Gongora-Rivera F, Santos Zambrano J, et al. Pre-treatment with corticosteroids and a single cycle of high dose albendazole for subarachnoidal cysticercosis. J Neurol Neurosurg Psychiatry 2004;75:938-9
71. Gongora-Rivera F, Soto-Hernandez JL, Gonzalez Esquivel D, et al. Albendazole trial at 15 or 30 mg/kg/day for subarachnoid and intraventricular cysticercosis. Neurology 2006;66:436-8
72. Cardenas G, Carrillo-Mezo R, Jung H, et al. Subarachnoidal Neurocysticercosis non-responsive to cysticidal drugs: a case series. BMC Neurol 2010;10:16
73. Miller B, Grinnell V, Goldberg MA, et al. Spontaneous radiographic disappearance of cerebral cysticercosis: three cases. Neurology 1983;33:1377-9
74. Kramer LD, Locke GE, Byrd SE, et al. Cerebral cysticercosis: documentation of natural history with CT. Radiology 1989;171:459-62
75. Fleury A, Gomez T, Alvarez I, et al. High prevalence of calcified silent neurocysticercosis in a rural village of Mexico. Neuroepidemiology 2003;22:139-45
76. Carpio A, Santillan F, Leon P, et al. Is the course of neurocysticercosis modified by treatment with antihelminthic agents? Arch Intern Med 1995;155:1982-8
77. Baranwal AK, Singhi PD, Khandelwal N, et al. Albendazole therapy in children with focal seizures and single small enhancing computerized tomographic lesions: a randomized, placebo-controlled, double blind trial. Pediatr Infect Dis J 1998;17:696-700
78. Baranwal AK, Singhi PD, Singhi SC, et al. Seizure recurrence in children with focal seizures and single small enhancing computed tomographic lesions: prognostic factors on long-term follow-up. J Child Neurol 2001;16:443-5
79. Singhi P, Ray M, Singhi S, et al. Clinical spectrum of 500 children with neurocysticercosis and response to albendazole therapy. J Child Neurol 2000;15:207-13
80. Padma MV, Behari M, Misra NK, et al. Albendazole in single CT ring lesions in epilepsy. Neurology 1994;44:1344-6
81. Carpio A, Kelvin EA, Bagiella E, et al. Effects of albendazole treatment on neurocysticercosis: a randomized controlled trial. J Neurol Neurosurg Psychiatry 2008;79:1050-5
82. Garcia HH, Pretell EJ, Gilman RH, et al. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med 2004;350:249-58
83. Abba K, Ramaratnam S, Ranganathan LN. Anthelmintics for people with neurocysticercosis. Cochrane Database Syst Rev 2010;CD000215
84. Marques MP, Takayanagui OM, Bonato PS, et al. Enantioselective kinetic disposition of albendazole sulfoxide in patients with neurocysticercosis. Chirality 1999;11:218-23
85. Schipper HG, Koopmans RP, Nagy J, et al. Effect of dose increase or cimetidine co-administration on albendazole bioavailability. Am J Trop Med Hyg 2000;63:270-3
86. Mirfazaelian A, Dadashzadeh S, Rouini MR. Effect of gender in the disposition of albendazole metabolites in humans. Eur J Clin Pharmacol 2002;58:403-8
87. Marques MP, Takayanagui OM, Lanchote VL. Albendazole metabolism in patients with neurocysticercosis: antipyrine as a multifunctional marker drug of cytochrome P450. Braz J Med Biol Res 2002;35:261-9
88. Castro N, Jung H, Medina R, et al. Interaction between grapefruit juice and praziquantel in humans. Antimicrob Agents Chemother 2002;46:1614-16
89. Castro N, Medina R, Sotelo J, et al. Bioavailability of praziquantel increases with concomitant administration of food. Antimicrob Agents Chemother 2000;44:2903-4
90. Jung H, Medina R, Castro N, et al. Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single-day therapeutic regimen. Antimicrob Agents Chemother 1997;41:1256-9
91. Lanchote VL, Garcia FS, Dreossi SA, et al. Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. Ther Drug Monit 2002;24:338-45
92. Lanchote VL, Marques MP, Takayanagui OM, et al. Simultaneous determination of albendazole sulfoxide enantiomers and albendazole sulfone in plasma. J Chromatogr B Biomed Sci Appl 1998;709:273-9
93. Paias FO, Lanchote VL, Takayanagui OM, et al. Enantioselective analysis of albendazole sulfoxide in plasma using the chiral stationary phase. Chirality 1997;9:722-6
94. Paias FO, Lanchote VL, Takayanagui OM, et al. Enantioselective analysis of albendazole sulfoxide in cerebrospinal fluid by capillary electrophoresis. Electrophoresis 2001;22:3263-9
95. Takayanagui OM, Bonato PS, Dreossi SA, et al. Enantioselective distribution of albendazole metabolites in cerebrospinal fluid of patients with neurocysticercosis. Br J Clin Pharmacol 2002;54:125-30
96. Odashima NS. Enatiomers of albendazole sulfoxide in plasma and cerebrospinal fluid: therapeutic efficacy in treatment of active neurocysticercosis. Thesis. Faculty of Medicine at Ribeirao Preto - University of Sao Paulo. Ribeirao Preto; Sao Paulo, Brazil: 2003
97. Cioli D. Chemotherapy of schistosomiasis: an update. Parasitol Today 1998;14:418-22
98. Lima RM, Ferreira MA, de Jesus Ponte Carvalho TM, et al. Albendazole-praziquantel interaction in healthy volunteers: kinetic disposition, metabolism and enantioselectivity. Br J Clin Pharmacol 2011;71:528-35
99. Palomares F, Palencia G, Ambrosio JR, et al. Evaluation of the efficacy of albendazole sulphoxide and praziquantel in combination on Taenia crassiceps cysts: in vitro studies. J Antimicrob Chemother 2006;57:482-8
100. Garcia HH, Lescano AG, Lanchote VL, et al. Pharmacokinetics of combined treatment with praziquantel and albendazole in neurocysticercosis. Br J Clin Pharmacol 2011;72:77-84